Dengue virus (DV) is a single-stranded RNA flavivirus that causes dengue fever, the most prevalent arthropod-borne viral illness in humans (NIAID Category A pathogen). Globally, the four serotypes of DV cause an estimated 100 million new cases of dengue fever and 250,000 cases of dengue hemorrhagic fever (DHF) per year, primarily in tropical and subtropical areas. Currently, no specific therapy is available for human use. Given its global burden, there is a pressing need for the development of safe therapeutics against DV. Recently, we defined a dominant neutralizing epitope on domain III of the envelope (E) protein o West Nile virus (WNV), a related flavivirus, and humanized one monoclonal antibody (Hu-E16) with clinical potential as a post-infection therapeutic. Hu-E16, which is now entering human clinical trials, binds to a conserved WNV-specific epitope, and neutralizes at a post-attachment step of infection. While in theory, antibody-based therapeutics could have analogous activity against DV, the risk for antibody-dependent enhancement of infection (ADE) with adverse outcome has limited this approach. For this proposal, we will use an existing academic-industry collaborative partnership to generate an antiviral biological product consisting of humanized monoclonal antibodies (mAbs) that potently neutralize all serotypes of DV without he risk of ADE.
In Specific Aim 1, we will generate mouse mAbs against the E protein of all four DV serotypes and test their relative neutralizing potential in vitro and in vivo.
In Specific Aim 2, we will identify recognition determinants on DV E proteins for the strongly inhibitory mAbs using high-throughput yeast surface display epitope mapping. Using this information, we will create DV variant strains that are resistant to mAb neutralization and test them for virulence.
In Specific Aim 3, we will humanize candidate inhibitory mAbs that strongly block infection against each DV serotype. These will be tested for neutralizing activity in cell culture and in mice.
In Specific Aim 4, we will engineer safe DV immunotherapeutics by altering the effector functions of candidate humanized mAbs. Cell lines producing IgG subclass variants will be developed that strongly neutralize yet abolish Fc receptor binding and prevent ADE. Overall, the generation of humanized mAbs against all four DV serotypes with no possibility of ADE will foster the development of potent and safe immunotherapeutics against DV infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI077955-04
Application #
8097933
Study Section
Special Emphasis Panel (ZAI1-TP-M (J2))
Program Officer
Cassetti, Cristina
Project Start
2008-06-25
Project End
2013-05-31
Budget Start
2011-06-01
Budget End
2013-05-31
Support Year
4
Fiscal Year
2011
Total Cost
$850,625
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Thiemmeca, Somchai; Tamdet, Chamaiporn; Punyadee, Nuntaya et al. (2016) Secreted NS1 Protects Dengue Virus from Mannose-Binding Lectin-Mediated Neutralization. J Immunol 197:4053-4065
Pinto, Amelia K; Brien, James D; Lam, Chia-Ying Kao et al. (2015) Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection. MBio 6:e01316-15
Zhang, Xinzheng; Sheng, Ju; Plevka, Pavel et al. (2013) Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci U S A 110:6795-9
Brien, James D; Sukupolvi-Petty, Soila; Williams, Katherine L et al. (2013) Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus. J Virol 87:7747-53
Smith, Scott A; de Alwis, A Ruklanthi; Kose, Nurgun et al. (2013) The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio 4:e00873-13
Pierson, Theodore C; Diamond, Michael S (2012) Degrees of maturity: the complex structure and biology of flaviviruses. Curr Opin Virol 2:168-75
Lobigs, Mario; Diamond, Michael S (2012) Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex. Expert Rev Vaccines 11:177-87
da Silva Voorham, Júlia M; Rodenhuis-Zybert, Izabela A; Ayala Nuñez, Nilda Vanesa et al. (2012) Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2. PLoS One 7:e29957
Shrestha, Bimmi; Austin, S Kyle; Dowd, Kimberly A et al. (2012) Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody. Virology 427:127-34
Balsitis, Scott J; Williams, Katherine L; Lachica, Ruben et al. (2010) Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6:e1000790

Showing the most recent 10 out of 14 publications